Theralase has developed patented anti-cancer Photo Dynamic Compounds (PDCs) that localize to cancer cell DNA and destroy it when activated by light, causing cell death with no observed side effects. Preclinical studies show PDC is up to 100,000 times more effective than FDA-approved drugs at killing various cancer cell types, including bladder cancer cells. Theralase plans to complete a Phase 1/2a human bladder cancer clinical trial in 2015 to validate PDC's safety and efficacy in humans. The goal is to then partner with a large pharmaceutical company in 2016 to commercialize PDC for bladder cancer treatment.

1. 1Q2014CONFIDENTIAL
Theralase Technologies Inc.
Roger Dumoulin‐White
Chapter Title Section
g
President, Chief Executive Officer
Chapter Title Section

2. Company
Anti Cancer Platform TechnologyAnti Cancer Platform Technology
Patented anti‐cancer drugs known as Photo Dynamic Compounds (PDCs) localize to the DNA of cancer cells and
when light activated destroy the DNA resulting in natural cell death (apoptosis)
HighlightsHighlights
Up to 100% cancer cell kill at very low concentrations (< 0.8µM)
Virtually 0% toxicity at high concentrations (> 100µM) leading to very high safety profile
More effective at killing cancer cells than FDA approved drugs (668,000 x ALA, 198 x PHOTOFRIN)
No side effects were observed from treatment (quick evacuation of PDC from healthy cells and high light fluence
required for activation provides extremely high safety profile)
Ult l t i it PDC t bl d t (bl dd )Ultra low toxicity as PDC never enters blood stream (bladder cancer)
Water soluble & readily penetrates cellular membrane (DNA localizing)
Activated by laser light providing excellent specificity and selectivity
Lethal to cancer and bacteria
Able to treat solid core hypoxic tumours, such as: breast, prostate and lung
Research performed at world renowned Princess Margaret Cancer Centre
Activated at long wavelengths (allows deeper tumour destruction)
Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
Pending USA Patent Applications: 61/801,674, 13/863,089, PCT/US13/36595

3. O i
Strategy
Opportunity
Complete a FDA Phase 1/2a human bladder cancer clinical study with FDA breakthrough status
Execution of a strategic partnering agreement with big pharma for destruction of bladder cancerExecution of a strategic partnering agreement with big pharma for destruction of bladder cancer
(i.e.: upfront payments , co‐development funds, annual recurring revenue streams)
Strategy
2013 ‐ Milestone 2 (complete): Destruction of cancer in a live animal mouse model. Demonstrated >99%
efficacy for a subcutaneous cancerous tumour
2014 ‐ Milestone 3 (in progress): Complete validation in orthotopic rat model, dose toxicity study, GMP drug
manufacture and FDA Investigational New Drug (IND) application
2015 ‐ Milestone 4: Complete FDA phase 1/2a human clinical study with FDA breakthrough status
2016 ‐ Milestone 5: Execute strategic partnering agreement with big pharma

4. Bladder Cancer
USA Bladder Cancer Treatment Annual SpendingUSA Bladder Cancer Treatment Annual Spending
$3.9 billion (2012)
Statistics
70,000 new cases, > 14,000 deaths in the US each year
386,000 new cases are diagnosed worldwide annually
Standard treatment unchanged with no new drugs approved since 1998
5th most common cancer, 4th in men, 8th in women
Most expensive cancer to treat with a recurrence rate up to 80%
70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell
Carcinoma (TCC)
Current Standard of Care
Early stage disease (Ta, T1): Trans Urethral Resection of the Bladder Tumour (TURBT) followed by treatment y g ( , ) ( ) y
with bacillus Calmette‐Guérin (BCG) – 5 year survival rate of 75%.
Mid Stage disease (T2, T3a/b): Entire bladder removed along with nearby reproductive organs and lymph
nodes in a procedure called a radical cystectomy ‐ 5 year survival rate of 31 to 63% depending on progression
of disease.
Late stage disease (T4): Disease has spread to distant sites, such as the bones, liver and lungs
and is generally regarded as incurable ‐ 5 year survival rate of 21%.

5. HT1376 Human Bladder Cancer Cell Line
Safety and Efficacy of PDC
Safety: PDC + No light Efficacy: PDC + LightSafety: PDC + No light Efficacy: PDC + Light
100
120
45 J cm‐2
90 J cm‐2
100
120 45 J cm‐2
90 J cm‐2
40
60
80
Cell Kill (%)
40
60
80
Cell Kill (%)
0
20
0.00125 0.0025 0.005 0.01 0.02 0.04
Concentration (mM)
0
20
0.00125 0.0025 0.005 0.01 0.02 0.04
Concentration (mM)Concentration (mM)

6. Safety: PDC + No Light Efficacy: PDC + Light Mouse colon cancer (carcinoma)
PDC Efficacy vs. ALA (FDA Approved Drug)
40
60
80
100
llKill(%)
ALA
14A
40
60
80
100
llKill(%)
ALA
TPDC
0
20
0.00016 0.0003 0.0008 0.025
Cel
Concentration (mM)
0
20
0.00016 0.0003 0.0008 0.025
Ce
Concentration (mM)
Human brain cancer (glioblastoma)
40
60
80
100
llKill(%)
40
60
80
100
Kill(%)
0
20
0.00016 0.0003 0.0008 0.025
Cel Concentration (mM)
0
20
40
0.00016 0.0003 0.0008 0.025
Cell
Concentration (mM)
Rat brain cancer (glioma)
40
60
80
100
Kill(%)
40
60
80
100
Kill(%)
0
20
40
0.0001 0.0002 0.0005 0.017
Cell
Concentration (mM)
0
20
40
0.0001 0.0002 0.0005 0.017
Cell
Concentration (mM)

7. Theralase PDC Efficacy vs. 2 FDA Approved Drugs
33
TLD1633
668 000 198668,000x more
effective than
ALA
198x more
effective than
PHOTOFRIN

8. Destruction of Cancer in Live Animal with PDC
PDC injection of 53 mg kg‐1 4hr Post PDC Injection
(Pre Light Activation)
T i d d iTumour induced in
animal (BALB/c mice )
with tumour reaching 5.0
 0.5 mm in size.
20 Months Post Treatment
24hr Post Light Activation
20 Months Post Treatment
(No recurrence)
Mice have survived 20Mice have survived 20
months cancer free after
only 1 PDC treatment

9. Preclinical
Live Animal SurvivalLive Animal Survival
Colon Cancer cells injected
Irradiation: λ=530 nm, 192 J
2013: $0 M
2014: $0 M
2015: $0 M
2016: $250 M
Investment
$10 M
ROI
2500% in 3 yrs
Investment vehicle
Joint venture with bladder cancer asset placed into an incorporated company with 50/50 ownership split
Survival of mice up to 20
months (50 human years)between Theralase and investment partner months (50 human years)
after one Theralase PDT
treatment

10. Scientific Risk
Anti‐Cancer Technology Risk
Scientific Risk
in‐vitro and small animal in‐vivo results show virtually zero toxicity and up to 100% cancer kill across a wide range of
cancers
Manufacturing Riskg
Drug manufacturing will be outsourced to a GMP facility. Laser design will be completed by Theralase which is ISO‐
13485 certified and has designed and manufactured laser systems for over 20 years. Manufacturing of sub
components will occur at ISO‐9001 manufacturing facilities
Regulatory RiskRegulatory Risk
Very low as anti‐cancer technology has demonstrated up to 100% effectiveness in bladder cancer cells with virtually
zero toxicity as it never enters the blood stream. FDA is very supportive of approving new cancer drugs
Financing Riskg
$3.15 M financing completed in November 2013 to commercialize next generation therapeutic laser and commence
Phase 1/2a anti‐cancer clinical trial
Liquidity Risk
l d h d k d f llCompany currently trades on the TSXV under ticker TLT and is a fully reporting issuer
Execution Risk
Outsourced to Princess Margaret Cancer Centre, one of the top 5 cancer institutes in the world. Canada’s top uro‐
oncologist and Head of Urology at Princess Margaret Cancer Centre will lead bladder cancer clinical trialsoncologist and Head of Urology at Princess Margaret Cancer Centre will lead bladder cancer clinical trials

11. Recent Pharma Deals
$1B + royalties July 2011 ‐ Worldwide rights to develop and
commercialize Bi‐specific T cell engager
antibodies against 2 solid tumour targets.
$964M +
royalties
Dec 2010 ‐ Exclusive rights to develop and
commercialize targeted covalent drugs for
t t t b d A il ’ A il icancer treatment based on Avila’s Avilomics
Technology.
$912M + Aug 2010 ‐Worldwide rights to develop and$912M +
royalties
Aug 2010 ‐Worldwide rights to develop and
commercialize cancer drug candidates using
Seattle Genetics’ antibody‐drug conjugate
program.
$815M +
royalties
Jan 2012 ‐ Collaboration to discover and develop
small molecule drugs against oncology‐relevant
t i t i i t ti
Note: Deals include up‐front, milestone and royalty payments on net sales.
protein‐protein interactions.

12. Recent Pharma Deals
$700 M +
royalties
Jan 2012 ‐ Collaboration to discover and develop
drugs that target tumor metabolism mechanisms.
$540 M +
royalties
June 2010 ‐ Rights to discover, develop and
commercialize novel anti‐cancer stem cell
therapeutics targeting the Wnt signaling pathway. p g g g g p y
$508 M +
royalties
Aug 2010 ‐ Exclusive worldwide rights to develop
and commercialize drug candidates arising from y g g f
its PD‐1 program for treatment of cancer.
$466 M + Oct 2010, Dec 2011 ‐ Exclusive worldwide rights to$466 M +
royalties
Oct 2010, Dec 2011 Exclusive worldwide rights to
discover, develop, manufacture and market TAP
compounds for the treatment of cancer.
Note: Deals include up‐front, milestone and royalty payments on net sales.

13. Company
Therapeutic Laser Platform TechnologyTherapeutic Laser Platform Technology
Designer and manufacturer of cold laser technology used to heal a wide range of nerve, muscle and joint conditions
(i.e.: Low Back Pain, Knee Osteoarthritis, Shoulder Tendonitis)
HighlightsHighlights
Used daily by thousands of practitioners worldwide
Millions of patients successfully treated
Superpulsed technology able to penetrate up to 4” into tissue (best in class)
Proven via clinical studies to eliminate pain, reduce inflammation and accelerate tissue healing through 3
independent cellular pathways (>90% efficacy)
FDA H lth C d d CE d f l i t 180 t iFDA, Health Canada and CE approved for sale into 180 countries
Large installed base of over 800 systems in Canada and 400 systems in the US and Internationally
Patented next generation therapeutic laser technology completed and launching 4Q 2014

14. Opportunity
Strategy
Opportunity
Expand sales and marketing into Western Canada and the 5 largest US States (30% of US GDP)
Commercialize next generation therapeutic laser (TLC‐2000)
$US pain market exceeds $100 Billion annually and is growing rapidly with aging population and rising
healthcare costs
Strategy
Launch Canadian sales and marketing offices in Toronto (complete), Calgary, Manhattan, Los Angeles, Tampa,
Houston and Chicago in 2014 and 2015
Expand manufacturing representatives and distributors across Canada and the US in non‐key territories
h h l h h h l dLaunch next generation TLC‐2000 therapeutic laser system through 800 existing Theralase customers in Canada
and 400 existing Theralase customers in US in 4Q2014
Displace competitive products through new sales and marketing offices in Canada and the US with next
generation TLC‐2000 therapeutic laser system in 2015

15. Theralase Therapeutic Laser Comparison
TLC‐1000
p p
Theralase
TLC ‐1007H
Microlight
ML‐830
Erchonia Quantum MEDX Meditech
Wavelength (nm) 905 and 660 830 635 635 785 840
Drive Platform /
FDA Approval
Super Pulse
/
NHN
Continuous
Wave / NHN
Continuous
Wave / NHN
Continuous
Wave / ILY
Continuous
Wave / ILY
Continuous
Wave / ILY /
NHN
Indicated Use Knee Pain
Hand and
Wrist Pain
Neck and
Shoulder Heat Heat
Heat /
Rotator Cuff
Wrist Pain
Pain Tendonitis
Average Power
(mW)
7 X 100 mW
6 x 25 mW
3 X 30 mW 2 X 5 mW 4 X 5 mW 16 X 5 mW
100 X 15
mW
Peak Power
( W)
50,000 mW 30 mW 10 mW 5 mW 5 mW 15 mW
(mW)
,
Total Actual
Tested Power
850 90 10 20 72 150
Photon Density
Per Laser Diode 5000 3 1 0.5 0.5 1.5Per Laser Diode
(W/cm2
)
5000 3 1 0.5 0.5 1.5
Approximate List
Price (USD)
$15,000 $10,000 $14,000 $12,000 $8,000 $30,000
Approximate cost
$17 $112 $1 400 $600 $112 $200
per mW (USD)
$17 $112 $1,400 $600 $112 $200

16. TLC‐2000
Next Generation Therapeutic Laser Launch 2014Next Generation Therapeutic Laser – Launch 2014
Dramatically improves efficacy over existing
Key Benefits
Dramatically improves efficacy over existing
technology by targeting tissue based on a
patient’s physical characteristics (patient
specific)
Allows migration from capital equipment model
to recurring revenue model
No up front fee, with $1,000 trade up allowance
to replace existing technology
2014 Objective: Installed base of 400 units at
$16,500 each, equates to $6.6 M in annual
revenue
USA Patent: 6,413,267, Canadian Patent: 2,315,521,
l i l i d i d iBelgium, Italy, United Kingdom, Germany, France, Spain
Patent: 1075854

17. 2013 PRACTITIONER SURVEY
Company
2013 PRACTITIONER SURVEY
20 Canadian and US Theralase customers (MDs, DCs, NPs PTs)
Survey Results
Practitioners charge between $25 to $75 per treatment (Average: $50)
Practitioners treat a single location 8 to 12 minutes per location (Average: 10 minutes)
Practitioners treat 100 to 400 patient treatments per month (Average: 200 treatments per month)
Summary
On average, Canadian and US medical practitioner utilize the Theralase therapeutic medical laser for 2000 minutes
per month charging patients $5 per minute, generating $10,000 in monthly revenue for their practice
At an average purchase price of $16,500 for the Theralase TLC‐2000 therapeutic medical laser system, the ROI is >
700%700%

18. Business Model
TLC‐2000
Business Model
No Up Front Fee
Practitioners sign a 42 month lease (6 payments @ $99 per month, followed by 36 payments at $500 + tax per
month) for the Professional Model, which allows for a $1,000 trade up allowance. Program includes: 42 month
i d 2 h k i d f 2 h i i hequipment warranty and 42 month marketing program. At end of 42 month term, customer must continue with
monthly payments into perpetuity or system ceases to operate.
Unlimited Use (Tracked through Internet)
10 treatments per month @ $50 per treatment covers cost of lease Medical practitioner retains all revenue in10 treatments per month @ $50 per treatment covers cost of lease. Medical practitioner retains all revenue in
excess of $500 per month (typically $10,000 per month generated from use of product)
Monthly report of usage per condition e‐mailed to customer with marketing support to increase usage per
condition
C l iConclusions
Practitioner Revenue: 200 patient treatments @ $50 per treatment = $10,000 monthly revenue
Practitioner Cost: $500 per month
Practitioner is generating 20X return on investment
2014 Objective
Installed base of 400 units financed initially through 42 month leases at $16,500 each equating to $6.6 M in
annual revenue

19. U S Healthcare Demographics
US Demographics
U.S. Healthcare Demographics
Healthcare Practitioners* 2008 2017 % increase
Veterinarians 59,700 79,400 33.0%Veterinarians 59,700 79,400 33.0%
Physical Therapists 185,500 241,700 30.3%
Medical Doctors 661,000 805,500 21.9%
Chiropractors 49,100 58,700 19.6%
Dentists 141,900 164,000 15.6%
Podiatrists 12,200 13,300 9.0%
Hospitals 5,795 5,795 0.0%
Total 1,115,195 1,368,395 18.5%
3,500 unit installed base
(target 2016) 0.31% 0.25%
* All statistics from the U.S. Bureau of Labor Statistics, Washington, DC, Occupational Outlook Handbook, 2010 – 2011 edition

20. Scientific Risk
Therapeutic Laser Technology Risk
Scientific Risk
Zero. Alpha prototype is already designed and patented.
Manufacturing Risk
Zero Laser manufacturing will be completed by Theralase which is ISO 13485 certified and has designed andZero. Laser manufacturing will be completed by Theralase which is ISO‐13485 certified and has designed and
manufactured laser systems for over 20 years.
Regulatory Risk
Zero. Current therapeutic laser technology is already FDA, Health Canada and CE approved. The next generation willZero. Current therapeutic laser technology is already FDA, Health Canada and CE approved. The next generation will
use these approvals for regulatory approval.
Financing Risk
Zero. $3.15 M financing completed in November 2013 to commercialize next generation therapeutic laser and
commence Phase 1 / 2a anti‐cancer clinical trial.
Liquidity Risk
Virtually zero. Company currently trades on the TSXV under ticker TLT and is a fully reporting issuer.
Execution Risk
Extremely Low. Theralase will displace its own technology in 2014 to achieve sales objectives. Theralase will displace
a small portion of competitive products to achieve 2015 and 2016 objectives.

21. Management Team
Management and Advisors
Board of DirectorsManagement Team
Roger Dumoulin‐White, P. Eng, President & CEO
Founded Theralase in 1995, 27+ years as a senior
manager with private and public companies
Arkady Mandel MD PhD DSc Chief Scientific
Board of Directors
S. Donald Moore –Director & senior officer to several public
companies
Roger Dumoulin‐White ‐ Company’s founder, President & CEO
with previous senior management experience with Ford Motor
Co.
Arkady Mandel, MD, PhD., DSc, Chief Scientific
Officer 21+ years experience as a key founder of
therapeutic uses of lasers in dermatology and other
areas of clinical medicine
Kristina Hachey, CGA, CFO
Randy Bruder ‐ Owner and operator of a wholesale / retail
operation for the last 25 years
Matt Perraton ‐ 13+ years of financial experience for TD
Waterhouse
17+ years of experience in finance and financings in
public and private companies
Wayne Embree, VP Engineering
38+ years of experience in designing and managing
design teams in the production of electronics devices
Guy Anderson ‐ 16+ years of financial experience with the
Investment Planning Counsel
Dr. James Andrews, American Sports Medicine Institute
Scientific & Medical Advisors
design teams in the production of electronics devices
Princess Margaret Cancer Centre ‐ University Health
Network
Dr. Jeffrey Dugas, American Academy of Orthopedic Surgeons,
ASMI, International Cartilage Repair Society
Kevin Wilk DPT, American Physical Therapy Association, ASMI
Dr. Lyle Cain, American Orthopedic Society for Sports Medicine,
Strong Strategic Partnerships
Ontario Centers of Excellence – Photonics
National Research Council ‐ IRAP
Virginia Tech
Michael Jewett MD, Professor of Surgery (Urology) at Univ. of
Toronto, Surgical Oncology at Princess Margaret Cancer Centre
Lothar Lilge PhD, Professor in the Department of Medical
Biophysics at the University of Toronto, Senior Scientist Ontario
Virginia Tech
Buffalo Niagara Medical Campus
Scripps Research Institute
Cancer Institute, Princess Margaret Cancer Centre

22. Investors
Why Invest?Why Invest?
Patented Technology
Patented anti‐cancer technology for bladder cancer
Patented next generation TLC‐2000 therapeutic laser technology
Large Market Opportunity
$$3.9 Billion bladder cancer treatment market in US, with no new drugs approved since 1998
$100 Billion pain market in US
Experienced Management Team
Experienced management team with ability to execute on strategic initiatives

23. Contact Information
h l h lTheralase Technologies Inc.
1945 Queen Street East
Toronto, Ontario, M4L 1H7
Canada
TLT:TSXV
Roger Dumoulin‐White
Founder President & CEOFounder, President & CEO
1‐866‐THE‐LASE (843‐5273) x225
rwhite@theralase.com
Common shares: 65,726,309
Stock price: $0.50
Market capitalization: $32.8 M
Auditors: Collins Barrows
Legal Counsel: Blaney McMurtry
Transfer Agent: TMX Equity

24. Forward Looking Statements
Forward Looking Statements
Forward Looking Statements
Certain statements contained or incorporated in this presentation, which deal with the Company’s financial condition
and operating results, include information, analyses and projections as to future corporate developments which are
currently in the planning stage, and on the projected operating financial performance of the Company, which
constitute forward looking statements Such forward looking statements made with special reference to theconstitute forward‐looking statements. Such forward‐looking statements, made with special reference to the
Company’s ongoing technologically complex healthcare and medical device research and development efforts, which
may include in‐house and independent clinical trials, testing new medical technologies and their applications, involve
known and unknown risks and uncertainties that could cause actual events and results to differ materially from those
estimated or anticipated and which may have been implied or expressed in such forward‐looking statements. No
conclusions as to the successful outcome of the ongoing and planned research and development projects in which the
C i i l d i d d i li d h b f di d i d fi i iCompany is involved are intended or implied nor can they be foreseen or predicted prior to definitive corporate
announcements as to their outcome. Certain forward looking statements are identified by words such as “believe”,
“anticipate”, “estimate”, “expect”, “intend”, “plan”, “expect”, “project”, “may”, and “will” and the negative of such
expressions, although not all forward looking statements contain these identifying words, any statements that refer to
expectations, projections or other characterizations of future events or circumstances are forward looking
statements. Although Theralase believes that the expectations reflected in any forward looking statements made ing p y g
this presentation are reasonable, such statement are based on a number of assumptions which may prove to be
incorrect, including, but not limited to assumptions relating to the risks and factors set out below. Accordingly, no
assurances can be given that any of the events or circumstances contemplated by any such forward looking
statements will transpire or occur or, if any of them transpire or occur or, if any of them transpire or occur, what
impact they will have on Theralase’s results of operations or financial condition. A more complete list of risks and
uncertainties inherent to the Company’s industry can be found in our MD&A reports listed on www sedarcomuncertainties inherent to the Company s industry can be found in our MD&A reports listed on www.sedar.com.
Furthermore, the forward‐looking statements contained in this presentation are made as of the date hereof and the
Company does not undertake any obligations to update publicly or to revise any of the included forward‐looking
statements, whether as a result of new information, future events, or otherwise. The forward‐looking statements
contained in this presentation are expressly qualified by this cautionary statement.p p y q y y
All references to dollars herein are to Canadian dollars except as otherwise indicated.